• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFR14A filed by Agenus Inc.

    5/5/25 4:15:11 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGEN alert in real time by email
    DEFR14A 1 d864776ddefr14a.htm DEFR14A DEFR14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    Agenus Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    EXPLANATORY NOTE

    This Amendment No. 1 to Schedule 14A (the “Amendment”) is being filed by Agenus Inc. (the “Company”) to amend the Company’s definitive proxy statement for the 2025 annual meeting of stockholders (the “Proxy Statement”), which was filed with the Securities and Exchange Commission on April 30, 2025. The Amendment corrects a scrivener’s error in the Proxy Statement, which includes the incorrect number of shares of the Company’s common stock outstanding as of the record date. The Proxy Statement, as filed, incorrectly stated the number of shares of the Company’s common stock outstanding as of the record date was 21,171,658. The correct number of shares of the Company’s common stock outstanding as of the record date is 27,171,658.

    No other changes have been made to the Proxy Statement or to the matters to be considered by the stockholders. All other items of the Proxy Statement are incorporated herein by reference without change. Capitalized terms used but not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Proxy Statement. This Amendment should be read in conjunction with the Proxy Statement.

    AMENDMENT TO PROXY STATEMENT

    All references to the number of shares of the Company’s common stock outstanding as of the Record Date contained in the Proxy Statement are hereby amended and restated to reflect 27,171,658 shares of the Company’s common stock were outstanding as of the Record Date.

    Get the next $AGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGEN

    DatePrice TargetRatingAnalyst
    6/4/2025$25.00Neutral → Buy
    H.C. Wainwright
    7/19/2024$35.00 → $8.00Outperform → Neutral
    Robert W. Baird
    7/18/2024Outperform → Mkt Perform
    William Blair
    7/18/2024$9.00Buy → Neutral
    H.C. Wainwright
    6/6/2023$8.00Outperform
    Robert W. Baird
    6/6/2023$60.00 → $80.00Outperform
    Robert W. Baird
    2/28/2023$8.00Buy
    H.C. Wainwright
    9/28/2022$5.00Outperform
    SMBC Nikko
    More analyst ratings

    $AGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

    VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal junction cancers last month, ushering in a new clinical paradigm for patients with historically resistant tumors [1]. Separately, the agency fast-tracked an experimental pancreatic cancer therapy based on early trial results showing tumors shrinking in nearly a third of patients[2]. These regulatory milestones position immunotherapy platforms capable of unlocking durable responses across multiple gastrointestinal malignancies as the next wave of commercial opportunity, drawing attention to developer

    12/12/25 10:31:03 AM ET
    $AGEN
    $CRDF
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

    Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET. The session will feature leading experts in gastrointestinal oncology and patient advocates discussing progress with the BOT/BAL program, emerging clinical insights, and the evolving treatment landscape for colorectal cancer. The session will be moderated by Garo Armen, PhD, Founder, Chairman, and CEO, and will conclude with a live Q&A. Questions can be submitted in advance to [email protected] Featured Topics and Speakers Role of Immuno-Oncolog

    11/19/25 4:01:00 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

    Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel (AAC) program. BOT is an Fc-enhanced multifunctional CTLA-4 antibody and BAL is a PD-1 antibody. In combination, BOT/BAL is being investigated in patients with microsatellite-stable colorectal cancer (MSS CRC), a population that has hi

    11/18/25 8:41:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    SEC Filings

    View All

    SEC Form 10-Q filed by Agenus Inc.

    10-Q - AGENUS INC (0001098972) (Filer)

    11/10/25 5:12:54 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AGENUS INC (0001098972) (Filer)

    11/10/25 7:32:25 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Agenus Inc.

    SCHEDULE 13G/A - AGENUS INC (0001098972) (Subject)

    10/30/25 2:24:21 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Armen Garo H was granted 3,587 shares, increasing direct ownership by 1% to 298,085 units (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    12/1/25 4:05:06 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Armen Garo H was granted 3,769 shares, increasing direct ownership by 1% to 294,498 units (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    11/17/25 4:05:04 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Armen Garo H was granted 4,120 shares, increasing direct ownership by 1% to 290,729 units (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    11/5/25 4:05:05 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Armen Garo H bought $324,050 worth of shares (500,000 units at $0.65) (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    2/15/24 6:59:48 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wiinberg Ulf bought $19,000 worth of shares (25,000 units at $0.76), increasing direct ownership by 25% to 124,063 units (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    11/17/23 4:22:11 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Agenus upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Agenus from Neutral to Buy and set a new price target of $25.00

    6/4/25 7:30:33 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously

    7/19/24 7:27:15 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus downgraded by William Blair

    William Blair downgraded Agenus from Outperform to Mkt Perform

    7/18/24 1:59:35 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

    Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel (AAC) program. BOT is an Fc-enhanced multifunctional CTLA-4 antibody and BAL is a PD-1 antibody. In combination, BOT/BAL is being investigated in patients with microsatellite-stable colorectal cancer (MSS CRC), a population that has hi

    11/18/25 8:41:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus Announces Appointment of Tom Harrison to Board of Directors

    Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran

    8/8/24 7:00:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors

    Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.

    6/17/24 7:00:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    Financials

    Live finance-specific insights

    View All

    Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

    France grants reimbursed access with patients having commenced treatment Two-year BOT/BAL survival presented at ESMO spanning more than five cancers in over 400 patients Phase 3 on track to commence in fourth quarter 2025 Agenus Inc. (NASDAQ:AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO‑GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial. Access & Regulatory Franc

    11/10/25 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

    Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus highlights of upc

    8/19/25 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

    Zydus Lifesciences collaboration to close in Q3 with $91M capital infusion to support clinical and regulatory milestones BOT/BAL delivers 42% two-year survival in refractory MSS CRC and consistent activity across multiple solid cancers, to be presented at an oral session at ESMO Regulatory alignment secured for Phase 3 trial initiation, expected to commence in Q4 2025 August 27th virtual stakeholder meeting set for a detailed discussion on progress Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2025 and highlighted major clinical, regulatory, and operational miles

    8/11/25 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agenus Inc.

    SC 13G/A - AGENUS INC (0001098972) (Subject)

    11/14/24 7:58:18 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Agenus Inc.

    SC 13G/A - AGENUS INC (0001098972) (Subject)

    11/14/24 9:21:26 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Agenus Inc. (Amendment)

    SC 13G/A - AGENUS INC (0001098972) (Subject)

    6/10/24 12:15:17 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care